Volume 21, Number 11—November 2015
Role of Maternal Antibodies in Infants with Severe Diseases Related to Human Parechovirus Type 31
|Preparation||Country†||Year obtained||IVIG treatment||NATs
|Batch 1||Japan||2010, 2011||PEG||1:1,024||1:512||1:2,048|
|Batch 2||Japan||2010||Freeze-dried PEG||1:1,024||1:512||1:1,024|
|Batch 3-2||Japan||2011, 2012||Sulfonation||1:1,024||1:1,024||1:2,048|
|Batch 4||United States||2012||Ion-exchange resin||1:1,024||1:512||1:2,048|
*HPeV1, human parechovirus type 1; IVIG, intravenous immunoglobulin; NATs, neutralizing antibody titers; PEG, polyethylene glycol.
†Country where IVIG was obtained.
1Presented in part at IDWeek, October 8–12, 2014, Philadelphia, Pennsylvania, USA.
Page created: October 16, 2015
Page updated: October 16, 2015
Page reviewed: October 16, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.